Genetic associations of protein-coding variants in human disease

1 2 3

4

5

6

Benjamin B. Sun^{*1,2}, Mitja I. Kurki^{3,4,5,6}, Christopher N. Foley^{7,8}, Asma Mechakra⁹, Chia-Yen Chen¹, Eric Marshall¹, Jemma B. Wilk¹, Biogen Biobank Team¹, Mohamed Chahine¹⁰, Philippe Chevalier⁹, Georges Christé⁹, FinnGen¹¹, Aarno Palotie^{3,4,5,6}, Mark J. Daly^{3,4,5,6}, Heiko Runz^{*1}.

- 7 1. Translational Biology, Research & Development, Biogen Inc., Cambridge, MA, US
- BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, 8 2. 9 University of Cambridge, Cambridge, UK
- 10 3. Psychiatric & Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, 11 US
- 12 4. The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, 13 MA. US
- 14 5. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
- 15 6. Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General 16 Hospital, Boston, MA, US
- 17 7. MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK
- 18 8. Optima Partners, Edinburgh, UK
- 19 9. Université Claude Bernard Lyon 1, EA4612 Neurocardiology, Lyon, France
- 20 10. CERVO Brain Research Center and Department of Medicine, Faculty of Medicine, Université 21 Laval, Quebec City, QC, Canada
- 22 11. FinnGen, Finland
- 23
- 24 *Correspondence: bbsun92@outlook.com (B.B.S.), heiko.runz@gmail.com (H.R.)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26 Genome-wide association studies (GWAS) have identified thousands of genetic variants linked 27 to the risk of human disease. However, GWAS have thus far remained largely underpowered 28 to identify associations in the rare and low frequency allelic spectrum and have lacked the 29 resolution to trace causal mechanisms to underlying genes. Here, we combined whole exome 30 sequencing in 392,814 UK Biobank participants with imputed genotypes from 260,405 31 FinnGen participants (653,219 total individuals) to conduct association meta-analyses for 744 disease endpoints across the protein-coding allelic frequency spectrum, bridging the gap 32 33 between common and rare variant studies. We identified 975 associations, with more than one-34 third of our findings not reported previously. We demonstrate population-level relevance for 35 mutations previously ascribed to causing single-gene disorders, map GWAS associations to 36 likely causal genes, explain disease mechanisms, and systematically relate disease associations 37 to levels of 117 biomarkers and clinical-stage drug targets. Combining sequencing and 38 genotyping in two population biobanks allowed us to benefit from increased power to detect 39 and explain disease associations, validate findings through replication and propose medical 40 actionability for rare genetic variants. Our study provides a compendium of protein-coding 41 variant associations for future insights into disease biology and drug discovery.

43 Introduction

44 Inherited protein-coding and non-coding DNA variations play a role in the risk, onset, and progression of human disease. Traditionally, geneticists have dichotomized diseases as either 45 46 caused by coding mutations in single genes that tend to be rare, highly penetrant, and often 47 compromise survival and reproduction (often termed "Mendelian" diseases), or alternatively 48 as common diseases that show a complex pattern of inheritance influenced by the joint 49 contributions of hundreds of low-impact, typically non-coding genetic variants (often termed 50 "complex" diseases). For both rare and common conditions, large human cohorts 51 systematically characterized for a respective trait of interest have enabled the identification of 52 thousands of disease-relevant variants through either sequencing-based approaches or genome-53 wide association studies (GWAS). Nevertheless, the exact causal alleles and mechanisms that 54 underlie associations of genetic variants to disease have thus far remained largely elusive¹.

55

56 In recent years, population biobanks have been added to the toolkit for disease gene discovery. 57 Biobanks provide the opportunity to simultaneously investigate multiple traits and diseases at 58 once and uncover relationships between previously unconnected phenotypes. For instance, the 59 UK Biobank (UKB) is a resource that captures detailed phenotype information matched to genetic data for over 500,000 individuals and, since its inception, has facilitated biomedical 60 discoveries at an unprecedented scale². We and others have recently reported on the ongoing 61 62 efforts to sequence the exomes of all UKB participants and link genetic findings to a broad range of phenotypes³⁻⁵. We also established FinnGen (FG), an academic-industry collaboration 63 64 to identify genotype-phenotype correlations in the Finnish founder population with the aim to 65 better understand how the genome affects health (https://www.finngen.fi). Finland is a wellestablished genetic isolate and a unique gene pool distinguishes Finns from other Europeans⁶. 66 67 The distinct Finnish haplotype structure is characterized by large blocks of co-inherited DNA

68 in linkage disequilibrium and an enrichment for alleles that are rare in other populations, but 69 can still be confidently imputed from genotyping data even in the rare and ultra-rare allele 70 frequency spectrum⁷⁻⁹. Through combining imputed genotypes with detailed phenotypes 71 ascertained through national registries, FG holds the promise to provide particular insights into 72 the yet little examined allele frequency spectrum between 0.1 and 2% where both sequencing 73 studies and GWAS have thus far remained largely underpowered to identify associations to 74 disease. This spectrum includes many coding variants with moderate to large effect sizes that 75 can help identify causal genes in GWAS loci, provide mechanistic insights into disease 76 pathologies, and potentially bridge rare and common diseases.

77

78 Here, we have leveraged the combined power of UKB and FG to investigate how rare and low-79 frequency variants in protein-coding regions of the genome contribute to the risk for human 80 traits and diseases. Using data from a total of 653,219 individuals, we tested how ~48,000 81 coding variants identified in both biobanks through either whole-exome sequencing (WES) or 82 genotype imputation associate with 744 distinct disease endpoints. Disease associations were 83 compared against information from rare disease, biomarker and drug target resources and 84 complemented by deep dives into distinct disease mechanisms of individual genes and coding 85 variants. Our results showcase the benefits of combining large population cohorts to discover 86 and replicate novel associations, explain disease mechanisms across a range of common and 87 rare diseases, and shed light on a substantial gap in the allelic spectrum that neither genotyping 88 nor sequencing studies have previously been able to address.

89

90 **Results**

91 An overview of the study design and basic demographics are provided in Extended Data
92 Figure 1 and Supplementary Table 1. In brief, we systematically harmonised disease

phenotypes across UKB and FG using Phecode and ICD10 mappings and retained 744 specific disease endpoints grouped into 580 disease clusters that span a broad range of diseases (Methods, Supplementary Table 2). Disease case counts relative to cohort size showed good correlations both, overall between UKB and FG (Spearman's ρ =0.65, p<5.3x10⁻⁹⁰) and across distinct disease groups (Extended Data Figure 2).

98

99 Coding-wide association analyses in 653,219 individuals across 744 disease 100 endpoints identify 975 genetic signals

We performed coding-wide association studies (CWAS) across 744 disease endpoints over a mean of 48,189 (range: 25,309-89,993, **Methods, Supplementary Table 2**) post-QC coding variants across the allele frequency spectrum derived from whole-exome sequencing (WES) of 392,814 European ancestry individuals in UKB and meta-analysed these data with summary results from up to 260,405 individuals in FG (**Methods, Supplementary Table 2**).

We identified 975 associations (534 variants in 301 distinct regions across 148 disease clusters; 107 108 620 distinct region-disease cluster associations) meeting genome-wide significance ($p < 5 \times 10^{-1}$ 109 ⁸), and 717 associations (378 variants in 231 distinct regions across 121 disease clusters; 445 110 distinct region-disease cluster associations) at a conservative (Bonferroni) multiple testing 111 threshold of $p < 2x10^{-9}$ (correcting for the number of approximate independent tests) (Methods, Figure 1a, Supplementary Figure 1 (interactive), Supplementary Table 3). The 112 113 distributions of coding variant annotation categories were largely similar for variants with at 114 least one significant association ($p < 5x10^{-8}$) relative to all variants tested, with missense variants showing a higher fraction of significant variants than in-frame indel or predicted loss-of-115 116 function (pLoF) variants (Extended Data Figure 3). Inflation was well controlled with a mean

117 genomic inflation factor of 1.04 (5-95 percentiles: 1.00-1.09, **Extended Data Figure 4a**). 118 Effect sizes were generally well aligned between UKB and FG (Spearman's ρ =0.90, p<10⁻³⁰⁰, 119 **Extended Data Figure 4b**). MAFs of lead variants correlated well overall between UKB and 120 FG (Spearman's ρ =0.97, p<10⁻³⁰⁰, **Figure 1b**), especially for variants with MAF>1%, yet as 121 expected⁸ from genetic differences between Finns and non-Finnish Europeans (NFEs) was 122 reduced for variants with MAF<1% (Spearman's ρ =0.32, p=0.023).

123

124 Across all diseases, we found generally larger effect sizes for low frequency and rare variants (Figure 1c). 387 of the 975 (39.7% at $p < 5x10^{-8}$; 270/717 (37.7%) at $p < 2x10^{-9}$) associations 125 would not have been detected if analysed in UKB (61.5% at $p>5x10^{-8}$; 60.1% at $p>2x10^{-9}$) or 126 FG (59.6% at $p>5x10^{-8}$; 58.6% at $p>2x10^{-9}$) alone. Association testing within UKB and FG 127 128 individually would have yielded 318 and 479 associations respectively at $p < 5x10^{-8}$ 129 (Supplementary Tables 4 and 5). Thus our combined approach utilizing both biobanks 130 increased the number of significant findings by approximately 3- and 2-fold, respectively. Of the 318 and 479 significant sentinel variants in UKB and FG, 252 (72.6%) and 258 (53.9%) 131 132 replicated at p < 0.05 in FG and UKB respectively (Supplementary Tables 4 and 5). highlighting further the strength of our approach to yield results that are more robust through 133 134 replication than would be findings derived from just a single biobank.

135

Our study benefits from population enrichment of rare alleles in Finns versus NFEs (and vice versa) that increases the power for association discovery. Using a combination of theoretical analyses and empirical simulations, we show that by leveraging population-enriched variants we could increase inverse-variance weighted meta-analysis Z-scores and hence our ability to detect underlying associations. The gain in power from enriched alleles was present across a range of rare MAFs (0.01-1%), with the strongest power gain in the rare and ultra-rare minor

allele frequency (MAF) range of 0.01% to 0.25% (Figure 1d, Supplementary Information,
Extended Data Figure 5, Supplementary Figure 2 (interactive)). Of the sentinel variants,
we found 73 (33 in UKB, 40 in FG) to be enriched by >2-fold and 23 (8 in UKB, 15 in FG)
by >4-fold relative to the respective other biobank (Figure 1b, Supplementary Table 6). The
majority of highly population enriched variants are rare (MAF<1%) or low frequency (MAF
1-5%), whereby 20 of 23 variants with >4-fold population enrichment (13 in FG and 7 in UKB)
had MAF <1% (Table 1, Supplementary Table 6).

149

150 We systematically cross-referenced our results with previously described GWAS associations (via GWAS Catalog¹⁰ and PhenoScanner¹¹) and disease relevance as reported in ClinVar¹² 151 152 (Methods). In total, we found that 216 of 620 (34.8%) distinct region-disease cluster associations had not previously been reported at $p < 5x10^{-8}$ (130/445 [29.2%] at $p < 2x10^{-9}$). Of 153 the 216 distinct loci, 177 (104/130 at $p \le 2x10^{-9}$) were in genes not previously mapped to the 154 155 respective diseases (Supplementary Table 3, Figure 1a, Supplementary Figure 1 156 (interactive)). Of the novel associations at GWAS significance ($p < 5x10^{-8}$), roughly one third 157 had MAF<5% in either UKB or FG and 15% had MAF<1% (Supplementary Table 3). 158 Importantly, 17% of known (UKB; 19% in FG), but 31% of novel (UKB; 28% in FG) 159 associations had a MAF<5%. Correspondingly, 5% of known (UKB; 6% in FG) and 15% of 160 novel (UKB; 10% in FG) associations had a MAF<1%, highlighting the power gained through 161 our approach especially in the low and rare allele frequency spectrum (Figure 1e, 162 Supplementary Table 3).

Mapping associations to genes, we found the majority of gene loci (81.2% at $p \le 5x10^{-8}$, MHC region counted as one locus) to be associated with a single disease cluster (**Extended Data Figure 6a**). Thirteen loci were associated with ≥ 5 trait clusters (at $p \le 5x10^{-8}$), including well

167 established pleiotropic regions such as the *MHC*, *APOE*, *PTPN22*, *GCKR*, *SH2B3* and *FUT2* 168 (**Figure 1a**). For instance, in addition to a known association with breast cancer, we found 169 variants in *CHEK2* as associated with the risk of colorectal and thyroid cancers, uterine 170 leiomyoma, benign meningeal tumours and ovarian cysts. Also, in addition to a known 171 association with prostate hyperplasia, we found an *ODF3* missense variant (rs72878024) to be 172 associated with risk of uterine leiomyoma, benign meningeal tumour, lipoma and polyps in the 173 female genital tract (**Supplementary Table 3**).

174

175 Harnessing the added power of UKB and FG, we were able to detect GWAS associations for 176 rare variants previously only annotated as causal for single-gene diseases, establishing a 177 disease relevance for these variants at the population level. Of the 534 distinct variants with 178 significant disease associations in our study ($p < 5x10^{-8}$), 152 had previously been linked to 179 diseases in ClinVar. For 45 of these variants, the associated disease cluster matched with a previously reported phenotype in ClinVar. Notably, only six of these 45 variants (in GJB2, 180 181 ABCC6, BRCA1, SERPINA1, FLG, and MYOC) had a previous annotation as either pathogenic or likely pathogenic (Supplementary Table 7), with 15 others annotated as benign. Of the 182 183 novel trait cluster associations, 17 had been reported in ClinVar for the same/similar diseases, 184 with 4 being classified as pathogenic/likely pathogenic and 13 classified either as benign or having "conflicting interpretation of pathogenicity" for the associated trait (Supplementary 185 186 Table 3, Supplementary Table 7). For instance, we found a rare missense variant annotated 187 as showing conflicting pathogenicity in ClinVar in VWF (rs1800386:C; Tyr1584Cys; MAF=0.44% [UKB], 0.47% [FG]) to be associated with the risk of von Willebrand disease¹² 188 $(\log[OR]=2.09, p=8.7 \times 10^{-9});$ or a missense variant in SPINK1 (rs17107315:C; Asn34Ser; 189 190 MAF=1.3% [UKB], 1.6% [FG]) annotated as showing conflicting pathogenicity in ClinVar for chronic pancreatitis to be associated with chronic pancreatitis risk¹² (log[OR]=1.16, $p=6.9\times10^{-1}$ 191

²⁵) and acute pancreatitis risk (log[OR]=0.69, $p=2.3 \times 10^{-18}$). These examples highlight that 192 193 population-scale analyses like ours can help refine pathogenicity assignments through 194 contributing quantitative information on relative disease risks for variant carriers. Likewise, 17 of the 23 genes with highly population-enriched sentinel variants (Table 1) were OMIM listed 195 196 disease genes. Of these, 10 (CHEK2, DBH, SCL24A5, CFI, FLG, XPA, F10, BRCA1, SCN5A, 197 CACNA1D) showed associations with conditions identical or related to the respective 198 Mendelian disease, unveiling a relevance of the associated variants on the population level. For 199 instance, we found the missense variant rs77273740 in DBH (enriched by >50x in FG), a gene 200 associated with orthostatic hypotension, to be associated with reduced risk of hypertension 201 $(\log[OR]=-0.19, p=1.3\times10^{-23})$, whilst an in-frame deletion (rs1250342280) in CACNA1D 202 (enriched by 4.3x in UKB), a gene associated with primary aldosteronism, was associated with 203 *increased* risk of hypertension (log[OR]= 0.19, $p=2.0x10^{-8}$) (Table 1).

204

Biomedical insights from coding variant associations

We leveraged the coding variant associations identified in our study to generate biological insights for a range of distinct genes, pathways and diseases and in the following exemplify the broad utility of our resource through a set of selected use cases.

209

210 New roles of coagulation pathway proteins in conferring pulmonary embolism risk

We found known and novel associations with pulmonary embolism (PE) risk, including two rare variant associations (average MAF<1%) in genes encoding components of the coagulation cascade at the convergent common pathway (**Figure 2a**). For instance, we discovered a rare missense mutation in *F10*, enriched by ~5-fold in FG (rs61753266:A; Glu142Lys; MAF=0.33% [UKB], 1.85% [FG]), to be protective against PE (log[OR]=-0.44, p=2.9x10⁻⁹). This variant has been associated with reduced plasma coagulation factor X (beta=-1.12, p=2.0x10⁻⁸) and

factor Xa (beta=-1.54, $p=7.9 \times 10^{-15}$) levels previously¹³, as well as clinical factor X deficiency¹⁴. 217 Deficiencies in coagulation factors, including factor X, are associated with increased bleeding 218 219 liability and reduced thrombotic risk. In a similar fashion, we found a previously reported 220 venous thromboembolism risk-reducing variant (rs4525:C; His865Arg; MAF=27.2% [UKB], 22.3% [FG]) in F5 that is also protective for PE (log[OR]=-0.14, $p=1.2 \times 10^{-15}$) and associated 221 with reduced plasma F5 levels¹⁵ (beta=-0.25, $p=6.0 \times 10^{-7}$). This variant acts opposite to the 222 well-established risk promoting F5 Leiden missense mutation, which leads to increased 223 resistance to activated protein C cleavage¹⁶ and thromboembolism liability, thus unravelling 224 225 that coding variants in F5 can have opposite effects on PE risk at the population level (Figure 226 2b). We performed Mendelian randomisation (MR) using rs4525 and rs61753266 as 227 instruments to estimate the relative reduction in PE risk due to reduced F5 (beta_{MR}=0.57, $p=1.0x10^{-15}$) and F10 levels (F10: beta_{MR}=0.40, p=2.9x10⁻⁹; F10a: beta_{MR}=0.28, p=2.9x10⁻⁹) 228 229 respectively (Figure 2b). MR results support the expected clinical indication of factor X 230 inhibitors in thromboembolic diseases and the hypothesis that developing drugs inhibiting 231 factor V will also likely be beneficial for PE. We also found a rare variant in fibrinogen (FGB 232 rs2227434:T; Pro100Ser; MAF=0.13% [UKB], 0.15% [FG], Figure 2a, Supplementary 233 Table 3) that associated with increased PE risk at nominal GWAS significance (log[OR]=1.03, 234 $p=1.5 \times 10^{-8}$). Missense mutations in FGB have previously been linked to both elevated and reduced fibrinogen levels through GWAS^{17,18}, as well as congenital afibrinogenemia¹⁹. 235

236

237 Rare variant biomarker associations yield insights into disease mechanisms

We interrogated the sentinel variants identified in this study for associations with 117 quantitative biomarkers spanning eight categories in UKB (**Supplementary Table 8**). At a multiple testing adjusted threshold of $p < 1 \times 10^{-6}$, we found 108 of the biomarkers to be associated with at least one of 417 sentinel variants across 239 regions (Figure 3a,

Supplementary Table 9). 47 of the regions were associated with 5 or more biomarker
categories (Extended Data Figure 6b, Supplementary Table 9), including pleiotropic
disease loci such as MHC, APOE, GCKR, SH2B3, FUT2, MCIR, ABCG5.

245

246 Many of the newly discovered associations with biomarkers are biologically plausible. For 247 example, a low-frequency missense variant in ADH1B (rs1229984:T; Arg48His; MAF=2.2% [UKB], 0.5% [FG]) that is associated with increased enzymatic activity of alcohol 248 249 dehydrogenase and reduced alcohol tolerance, is also associated with reduced risk of alcoholrelated disorders (alcoholic liver disease: $\log[OR]=-1.08$, $p=1.5\times10^{-9}$; mental and behavioural 250 disorders due to alcohol: $\log[OR]=-0.82$, $p=1.2x10^{-33}$) and increased risk of gout 251 252 $(\log[OR]=0.39, p=3.3\times10^{-10})$. Notably, the alcohol dependence disorder-promoting ADH1B allele (C) is also associated with reduced IGF-1 (beta=-0.11, $p=1.5 \times 10^{-51}$) and vitamin D levels 253 (beta=-0.049, $p=2.6 \times 10^{-10}$), increased levels of liver enzymes (alkaline phosphatase: 254 beta=0.087, $p=3.1\times10^{-37}$; gamma-glutamyl transferase: beta=0.041, $p=1.62\times10^{-9}$) and total 255 256 bilirubin (beta=0.031, $p=5.1\times10^{-7}$), macrocytosis with increased mean corpuscular volume 257 (beta=0.047, p=4.2x10⁻¹²) and mean corpuscular haemoglobin (beta=0.048, p=1.4x10⁻¹²), as well as reduced erythrocyte count (beta=-0.034, $p=3.2\times10^{-8}$). The gout risk reducing C allele 258 259 is associated with reduced urate levels (beta=-0.061, $p=1.4 \times 10^{-21}$).

260

261 A deletion in SLC34A1 is associated with multiple blood and urinary abnormalities

Cross-referencing with biomarkers provided mechanistic insights into novel findings. For instance, we discovered a novel association between a low frequency in-frame deletion in *SLC34A1* (rs1460573878, also known as rs876661296; MAF=2.6% [UKB], 2.7% [FG]; p.Val91_Ala97del) coding for the type II sodium phosphate cotransporter, NPT2a, which is expressed specifically in renal proximal tubular cells, to be associated with increased risk of

renal (log[OR]=0.24, p=4.0x10⁻⁹) and urinary tract stones (log[OR]=0.21, p=6.8x10⁻⁹). The 267 deletion has previously been implicated in hypercalciuric renal stones^{20,21} and autosomal 268 recessive idiopathic infantile hypercalcaemia²² in family studies. The variant is also associated 269 with increased serum calcium (beta=0.047, $p=5.4x10^{-11}$) and reduced phosphate (beta=-0.075, 270 $p=3.3 \times 10^{-26}$), consistent with a disrupted function/cell surface expression of the transporter²² 271 272 (Figure 3b). We further find associations with increased levels of serum urate (beta=0.048, $p=4.5 \times 10^{-17}$), suggesting an increased risk also of uric acid stones. Additionally, we found 273 associations with increased erythrocyte count (beta=0.035, $p=4.7 \times 10^{-10}$), haemoglobin 274 concentration (beta=0.033, $p=7.7 \times 10^{-10}$) and haematocrit percentage (beta=0.036, $p=9.9 \times 10^{-11}$), 275 276 suggesting increased renal-driven erythropoiesis (Figure 3b). Serum creatinine was not 277 increased in carriers of the deletion (beta=-0.07, $p=3.6 \times 10^{-33}$), suggesting renal function is not adversely affected in deletion carriers. Amongst 11,114 renal/ureteric and 13,319 urinary tract 278 279 stone cases, we identified 735 (renal/ureteric) and 863 (urinary tract) carriers of the deletion who may benefit from clinical interventions targeting NPT2a related pathways and monitoring 280 281 for deranged biochemical and haematological biomarkers.

282

283 A CHEK2 deletion is associated with blood cell counts and haematological malignancies

284 A frameshift deletion in CHEK2 (rs555607708; MAF=0.64% [FG], 0.24% [UKB]) that increases breast cancer risk has been previously implicated also in myeloproliferative 285 neoplasms through GWAS²³ and lymphoid leukaemia in a candidate variant study²⁴. 286 287 Consistently, we found nominally significant associations with risks of both, myeloid $(\log[OR]=1.52, p=9.5\times10^{-8})$ and lymphoid $(\log[OR]=1.38, p=3.1\times10^{-7})$ leukaemia, but also 288 289 multiple myeloma (log[OR]=1.07, $p=5.1 \times 10^{-5}$) and non-Hodgkin lymphoma (log[OR]=0.81, $p=4.7 \times 10^{-4}$). Association of rs555607708 with clinical haematology traits showed statistically 290 291 significant associations with increased blood cell counts for both, myeloid (leukocytes,

neutrophils, platelets at $p < 1 \times 10^{-6}$; monocyte and erythrocytes at $p < 1 \times 10^{-3}$) and lymphoid 292 293 (lymphocytes, $p=5.7 \times 10^{-17}$) lineages (Figure 3c). Furthermore, we found associations with increased mean platelet volume (MPV, $p=1.3 \times 10^{-16}$) and platelet distribution width (PDW, 294 295 $p=5.2 \times 10^{-13}$), consistent with increased platelet activation and previous associations of MPV and PDW with chronic myeloid leukaemia²⁵. We also found associations with decreased mean 296 corpuscular haemoglobin ($p=7.8\times10^{-12}$) and mean corpuscular volume ($p=5.3\times10^{-10}$), 297 suggesting predisposition to haematological cancers by loss-of CHEK2 function is 298 299 accompanied by a microcytic red blood cell phenotype (Figure 3c).

300

301 Coding variant associations inform drug discovery and development

302 We cross-referenced genes with significant coding variant associations with drug targets using the therapeutic targets database²⁶. We found 66 genes with trait cluster associations that are the 303 304 targets of either approved drugs (26 genes) or drugs currently being tested in clinical trials (40 305 genes), among these, 14 in phase 3 trials (Supplementary Table 10). We found a statistical 306 enrichment for significant genes in our study to also be approved drug targets (26/482; 307 compared with a background of 569 approved targets/19,955 genes, OR=1.9, p=0.0024), which 308 is in line with previous estimates of a higher success rate for drug targets supported by genetics 27,28. Sensitivity analyses using more stringent association *p*-value thresholds further 309 increased these probability estimates ($p=5x10^{-9}$ [OR 2.3, p=0.00070]; $p=5x10^{-10}$ [OR 2.5, 310 311 p=0.00037], supporting previous observations that the stronger the genetic association, the 312 higher the likelihood of therapeutic success (Supplementary Table 11). In addition to 313 providing further support for well-established drug target associations such as between PCSK9 314 loss-of-function and hypercholesterolaemia, or F10 loss-of-function and venous 315 thromboembolism, we also found an association between a common missense variant 316 (rs231775:G) in CTLA4 with increased risk of thyrotoxicosis (log[OR]=0.12, $p=8.5 \times 10^{-13}$).

Since this variant is also a blood eQTL for decreased *CTLA4* expression²⁹ (Z-score=-6.91, $p=5.0x10^{-12}$), the association between genetic CTLA4 reduction and thyroid dysfunction might contribute to the adverse event of hyperthyroidism in cancer patients treated with CTLA4 inhibitors³⁰.

321

322 Genetics can inform drug discovery also on alternative indications for repurposing. For example, TYK2 inhibitors are being tested in clinical trials for various autoimmune and 323 psoriatic diseases³¹. Consistent with previous GWAS¹⁰, we found a missense variant in *TYK2* 324 325 (rs34536443:C) to be associated with reduced risk of rheumatoid arthritis and psoriatic diseases (Supplementary Table 3). Our analyses establish this variant to also be associated with 326 327 sarcoidosis (log[OR]=-0.41, p=3.6x10⁻⁸), proposing sarcoidosis as a new indication for *TYK2* 328 inhibitors. Similarly, while the pleiotropy of CHEK2 provides support for exploring CHEK2 329 inhibitors against a broader spectrum of malignancies, our analyses also highlight a risk for 330 potential haematological perturbations upon CHEK2 inhibitor treatment.

331

332 Genetic insights into atrial fibrillation

Atrial fibrillation (AF) GWAS have yielded a sizeable number of loci^{32,33}. We chose AF to exemplify how results from our study can further elucidate the genetics and biological basis of one distinct human trait, with a particular emphasis on how our results might help to disambiguate AF loci to causal genes and explain the functional significance of coding variant associations. Indeed, we report several coding variant associations (**Supplementary Table 3**) where prior GWAS ^{32,33} had fallen short to resolve GWAS loci to coding genes and explain disease mechanisms.

341 A binding motif disrupting missense variant reveals a role for METTL11B methylase in AF

The AF GWAS sentinel variant rs72700114 is an intergenic variant located between 342 343 METTL11B and LINC01142³²⁻³⁴. Our study unveiled a low frequency missense variant in METTL11B (rs41272485:G; Ile127Met; MAF=3.9% [UKB], 3.8% [FG]) as associated with 344 increased AF risk (log[OR]=0.14, $p=4.0 \times 10^{-11}$). METTL11B is a N-terminal monomethylase 345 346 that methylates target proteins containing an N-terminal [Ala/Pro/Ser]-Pro-Lys motif³⁵. The 347 missense variant Ile127Met (SIFT=0, PolyPhen=1.0) falls within a conserved motif in the 348 enzyme's S-adenosylmethionine/S-adenosyl-1-homocysteine ligand binding site³⁶. *METTL11B* 349 expression is enriched in heart and skeletal muscles with highest expression in heart muscle, in particular cardiomyocytes^{37,38}. We scanned protein sequences for a presence of the 350 351 [Ala/Pro/Ser]-Pro-Lys motif and elevated expression in cardiomyocytes (Methods, Supplementary Table 12). We found statistically significant enrichment of genes encoding 352 353 [Ala/Pro/Ser]-Pro-Lys motif containing proteins amongst genes with elevated expression in 354 cardiomyocytes (OR=1.34, 95% CI=[1.16, 1.54], p=3.2x10⁻⁵), many of which show N-355 terminal [Ala/Pro/Ser]-Pro-Lys motifs (OR=1.24, 95% CI=[1.06, 1.44], p=5.6x10⁻³). This group included several well-established AF genes³⁹ such as potassium channels (KCNA5, 356 KCNE4, KCNN3), sodium channels (SCN5A, SCN10A), NPPA, and TTN. Our data support 357 METTL11B as the causal gene in this GWAS locus and a relevance for N-terminal 358 359 [Ala/Pro/Ser]-Pro-Lys methylation in cardiomyocytes for AF.

360

361 Rare variants unveil causal mechanisms in SCN5A-SCN10A and HCN4-REC114 AF loci

Within the *SCN5A-SCN10A* locus, we replicated a common missense variant in *SCN10A* (rs6795970:A; Ala1073Val; MAF=40.0% [UKB], 44.6% [FG]) that was previously described to prolong cardiac conduction⁴⁰. Additionally, we found associations with reduced AF risk (log[OR]=-0.06, $p=2.1\times10^{-12}$), reduced pulse rate (beta=-0.02, $p=4.8\times10^{-18}$), and a suggestive

366 signal for increased risk of atrioventricular block ($\log[OR]=0.10$, $p=1.9\times10^{-7}$). On top of this, 367 we discovered a rare, FG enriched missense variant (rs45620037:A; Thr220Ile; MAF=0.11% 368 [UKB], 0.47% [FG]; SIFT=0.03, PolyPhen=0.96) in SCN5A, encoding the cardiac sodium 369 channel Na_V1.5, as associated with decreased risk of AF ($\log[OR]=-0.65$, $p=1.3\times10^{-12}$). The variant lies in the S4 voltage sensing segment of the first transmembrane domain of SCN5A⁴¹ 370 371 and leads to a substitution of the polar Thr to a non-polar Ile residue, most probably causing loss of function and electrophysiological changes^{42,43}. The Thr220Ile variant has been 372 associated with dilated cardiomyopathy⁴⁴ and conduction defects including sick sinus 373 syndrome and atrial standstill⁴⁵ in family studies with bradycardic changes. Consistently, we 374 375 found a nominal association with reduced pulse rate (beta=-0.078, p=0.023), suggesting that 376 protective effects of the variant will be most beneficial for the common tachycardic form of 377 AF through reducing pulse rate. Notably, our results identify both, SCN5A and SCN10A as 378 likely causal genes at this AF locus.

379

380 Another AF GWAS locus is tagged by the common intergenic sentinel variant rs74022964 381 between HCN4 and REC114^{32,33}. We identified a rare, FG enriched variant in HCN4 (rs151004999:T; Asp364Asn; MAF=0.045% [UKB], 0.17% [FG]; SIFT=0.05, PolyPhen=0.41) 382 383 associated with increased AF risk (log[OR]=0.72, $p=2.8\times10^{-8}$). HCN4 is a as hyperpolarization-activated ion channel contributing to cardiac pacemaker (funny) currents (I_f). 384 385 Mutations in HCN4 have been associated with familial bradycardia (also known as sick sinus syndrome 2) and Brugada syndrome 8 in family studies⁴⁶. Consistently, in our study we also 386 found an association with decreased heart rate (beta=-0.49, $p=3.8 \times 10^{-21}$). 387

389 Genetic variants underlying AF risk differentially modulate pulse rate

390 To further evaluate the hypothesis that distinct genetic mechanisms underlying AF risk 391 inversely modulate pulse rate, we applied clustered Mendelian randomization (MR-Clust)⁴⁷ 392 with a slight modification to the mixture-model to better accommodate rare-variants. 393 Specifically, we related expectation maximization clustering of AF associated variants with 394 homogenous directional effects on pulse rate (Methods). Among the AF sentinel variants from 395 our coding variant association analyses, we found the two above described clusters of variants 396 in SCN10A (rs6795970) and HCN4 (rs151004999), suggestive of two genetic components of AF that can increase and decrease pulse rate, respectively (Figure 4a, left). Identifying 397 398 components of AF with diverging directionality on pulse rate is not surprising given clinically AF can be driven by both tachycardia and bradycardia through distinct mechanisms⁴⁸. As 399 sensitivity analyses, we used sentinel variants from a recent AF GWAS³² where the candidate 400 401 gene sets overlapped those in our study and found concordant patterns (Figure 4a, left-middle, Supplementary Table 13). We also included all sentinel variants in the AF GWAS loci³² and 402 403 found additional clusters with differing impact on pulse rate (Figure 4a, right-middle). 404 Conversely, as expected, permuting pulse rate led to no clustering and null associations between AF and pulse (Figure 4a, right). Expectedly, within the AF GWAS loci³² the two 405 406 rare missense alleles in HCN4 (rs151004999:T, log[OR]=0.72) and SCN5A (rs45620037:A, 407 log[OR]=-0.65) identified in our study had much larger effect sizes on AF risk than the respective non-coding sentinel GWAS variants (rs74022964:T [HCN4 locus], log[OR]=0.12; 408 409 rs6790396:C [SCN5A, SCN10A locus], log[OR]=-0.058) (Figure 4a).

410

411 PITX2c Pro41Ser increases AF risk through a gain-of-function mechanism

412 Lastly, we found a rare missense variant in *PITX2* as associated with increased risk of AF

413 $(\log[OR]=0.38, p=1.1\times10^{-9})$. This variant is enriched nearly 50-fold in FG (rs143452464:A;

414 Pro41Ser; MAF=0.023% [UKB], 1.1% [FG]) and was independently identified in a French 415 family with AF (Supplementary Information, Supplementary Figure Pro41Ser 1), whilst 416 GWAS had linked intergenic variants between PITX2 and FAM241A to AF risk. PITX2 is a 417 bicoid type homeobox transcription factor previously assumed to play a role in cardiac rhythm 418 control⁴⁹. The Pro41Ser variant lies in the N-terminal domain that is only present in the PITX2c 419 isoform expressed in cardiac muscle (Figure 4b left). We performed reporter assays comparing 420 the ability of Xpress-PITX2c constructs to transactivate a luciferase reporter plasmid 421 containing a putative PITX2c binding element (Supplementary Information). A construct 422 containing the Pro41Ser variant showed a ~2.4-fold higher activation of the reporter than the 423 wild-type construct (p=0.006, Figure 4b middle). This effect was abrogated upon deletion of 424 the putative PITX2c binding site (Figure 4b middle; see also Supplementary Information, 425 Supplementary Figure Pro41Ser 2 and Supplementary Figure Pro41Ser 3). In cultured 426 cardiac muscle HL-1 cells, Pro41Ser increased the transcription of several presumed PITX2c 427 target genes, specifically GJA1 (Cx40, 1.76-fold, p=0.012), GJA5 (Cx43, 1.85-fold, p=0.005) 428 and KCNH2 (1.81-fold, p=0.009), while the transcription of other selected genes with putative 429 roles in AF was not substantially altered (Figure 4b right, Supplementary Table 14, see also 430 Supplementary Information). Together, these results are consistent with a putative gain-of-431 function mechanism of Pro41Ser on PITX2c transactivation potential and AF risk.

432

433 **Discussion**

Here, we have conducted the to date largest association study of protein-coding genetic variants against hundreds of disease endpoints ascertained from two massive population biobanks, UK Biobank and FinnGen. We report novel disease associations, most notably in the rare and low allelic frequency spectrum, replicate and assign putative causalities to many previously reported GWAS associations, and leverage the insights gained to elucidate disease

mechanisms. In addition to a substantial gain in power over previous studies, our analyses
benefit from replication between two population cohorts, increasing the robustness of our
findings and setting the stage for future similar studies in ethnically more diverse populations.

443 Importantly, our study identifies both, pathogenic variants residing in monogenic disease genes 444 to impact the risk for related complex conditions, as well as new, likely causal sentinel variants 445 within GWAS loci in genes with known and novel biological roles in the respective GWAS 446 trait. With this, our study is one of the first to help bridge the gap between common and rare 447 disease genetics across a broad range of conditions and provides support for the hypothesis that the genetic architecture of many diseases is continuous¹. As reflected in a recent schizophrenia 448 449 study⁵⁰, GWAS tend to identify association signals primarily for variants with MAF>2%, while 450 most variants identified through exome sequencing are ultra-rare (MAF<0.01%). Of the 975 451 associations identified in our study, 145 are driven by unique variants in the yet little 452 interrogated rare and low allelic frequency spectrum that is hypothesized to contribute substantially to the "missing heritability" of many human diseases⁵¹. 453

454

455 Our approach benefits considerably from the Finnish genetic background where, consistent 456 with previous observations⁶⁻⁸, certain alleles are stochastically enriched to unusually high allele 457 frequencies, at times exceeding population frequencies in the UK Biobank by >50-fold (such 458 as for instance the *PITX2*-Pro41Ser variant). Our theoretical and empirical results suggest the 459 increasing utility of enriched variants for identifying associations quantitatively towards lower 460 allelic frequencies. Notably, we identify the most prominent relative power gain in the rarest 461 variant frequency spectrum, highlighting a role for sequencing studies and integrating 462 additional population cohorts with enriched variants for identifying novel disease associations 463 at scale. In our study, we identify several alleles with comparatively high effect sizes and a

464 prevalence in the population that warrants follow-up, both experimentally as well as potentially 465 directly in clinical settings to help improve disease outcomes. For instance, our data propose 466 that 6.5% of UKB and FG participants with kidney or urinary tract stones, conditions debilitating >15% of men and 5% of women by 70 years of age^{52} , carry a deletion in *SLC34A1*. 467 468 Monitoring patients for the clinical biomarkers identified here as associated with this deletion 469 might help to differentiate aetiologies and guide individualized treatments. Likewise, coding 470 variant associations identified in our study may serve as an attractive source to generate hypotheses for drug discovery programs. Our results support previous studies^{27,28} that drug 471 472 targets supported by human genetics have an increased likelihood of success, which can be 473 considered particularly high when the genetic effect on a drug target closely mimics that of a 474 pharmacological intervention⁵³.

475

We demonstrate the broad utility of our results through numerous examples. For instance, in 476 477 the case of AF we show how coding variants can help disambiguate GWAS loci to likely causal 478 genes and in some cases predict specific changes in a protein's function; how integration of 479 genetics with intermediate traits (such as slow versus fast heart rate) can unravel different 480 biological mechanisms underlying a disease entity; or how a putative function of sentinel 481 coding variants can be further validated through experiments. Our examples highlight that the 482 step from association to biological insight may be considerably shorter for coding variant 483 association studies than it has traditionally been for GWAS.

484

The results of our study foreshadow the discovery of many additional coding and non-coding associations from cross-biobank analyses at even larger sample sizes. With the continued growth of population biobanks with comprehensive health data also in non-European populations, the emergence of more and more cost-effective technologies for sequencing and

- 489 genotyping, and computational advances to analyse genetic and non-genetic data at scale,
- 490 future studies will be able to assess the genetic contribution to health and disease at even finer
- 491 resolution.
- 492

493 Methods

494 Samples and participants

495 UK biobank (UKB) is a UK population study of approximately 500,000 participants aged 40-69 years at recruitment². Participant data include genomic, electronic health record linkage, blood, urine and infection biomarkers, physical and anthropometric measurements, imaging data and various other intermediate phenotypes that are constantly being updated. Further details are available at <u>https://biobank.ndph.ox.ac.uk/showcase/</u>. Analyses in this study were conducted under UK Biobank Approved Project number 26041.

501

502 FinnGen (FG) is a public-private partnership project combining electronic health record and registry data from six regional and three Finnish biobanks. Participant data include genomics 503 504 and health records linked to disease endpoints. Further details are available at 505 https://www.finngen.fi/. More details on FG and ethics protocols are provided in 506 Supplementary Information. We used data from FG participants with completed genetic 507 measurements (R5 data release) and imputation (R6 data release). FinnGen participants 508 provided informed consent for biobank research. Recruitment protocols followed the biobank 509 protocols approved by Fimea, the National Supervisory Authority for Welfare and Health. The 510 Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) 511 approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by 512 Finnish Institute for Health and Welfare.

513

514 **Disease phenotypes**

515 FG phenotypes were automatically mapped to those used in the Pan UKBB 516 (<u>https://pan.ukbb.broadinstitute.org/</u>) project. Pan UKBB phenotypes are a combination of

Phecodes⁵⁴ 517 and ICD10 codes. Phecodes translated ICD10 were to 518 (https://phewascatalog.org/phecodes icd10, v.2.1) and mapping was based on ICD-10 519 definitions for FG endpoints obtained from cause of death, hospital discharge and cancer 520 registries. For disease definition consistency, we reproduced the same Phecode maps using the 521 same ICD-10 definitions in UKB. In particular, we expertly curated 15 neurological 522 phenotypes using ICD10 codes. We retained phenotypes where the similarity score (Jaccard 523 index: $ICD10_{FG} \cap ICD10_{UKB}$ / $ICD10_{FG} \cup ICD10_{UKB}$) was >0.7 and additionally excluded 524 spontaneous deliveries and abortions.

525

526 Phecodes and ICD10 coded phenotypes were first mapped to unified disease names and disease 527 groups using mappings from Phecode, "PheWAS" and "icd" R packages followed by manual 528 curation of unmapped traits and diseases groups, mismatched and duplicate entries. Disease 529 endpoints were mapped to Experimental Factor Ontology (EFO) terms using mappings from 530 EMBL-EBI and Open Targets based on exact disease entry matches followed by manual 531 curation of unmapped traits.

532

533 Disease trait clusters were determined through first calculating the phenotypic similarity via 534 the cosine similarity, then determining clusters via hierarchical clustering on the distance 535 matrix (1-similarity) using the Ward algorithm and cutting the hierarchical tree, after inspection, 536 at height 0.8 to provide the most semantically meaningful clusters.

537

- 538 Genetic data processing
- 539 UKB genetic QC

540 UKB genotyping and imputation were performed as described previously². WES data for UKB
541 participants were generated at the Regeneron Genetics Center (RGC) as part of a collaboration

542 between AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, 543 Pfizer, Regeneron and Takeda with the UK Biobank. WES data were processed using the RGC SBP pipeline as described in ^{3,55}. RGC generated a QC-passing "Goldilocks" set of genetic 544 545 variants from a total of 454,803 sequenced UK Biobank participants for analysis. Additional 546 QC were performed prior to association analyses as detailed below. 547 548 FG genetic QC 549 Samples were genotyped with Illumina (Illumina Inc., San Diego, CA, USA) and Affymetrix 550 arrays (Thermo Fisher Scientific, Santa Clara, CA, USA). Genotype calls were made with GenCall and zCall algorithms for Illumina and AxiomGT1 algorithm for Affymetrix data. 551 552 Sample, genotyping as well as imputation procedures and QC are detailed in Supplementary 553 Information. 554 555 **Coding variant selection** GnomAD v.2.0 variant annotations were used for FinnGen variants⁵⁶. The following gnomAD 556 annotation categories are included: predicted loss-of-function (pLoF), low-confidence loss-of-557 558 function (LC), in-frame indel, missense, start lost, stop lost, stop gained. Variants have been 559 filtered to imputation INFO score > 0.6. Additional variant annotations were performed using variant effect predictor (VEP)⁵⁷ with SIFT and PolyPhen scores averaged across the canonical 560 561 annotations. 562

563 **Disease endpoint association analyses**

For optimized meta-analyses with FG, analyses in UKB were performed in the subset of exome-sequence UKB participants with white European ancestry for consistency with FG (n=392,814). We used REGENIE v1.0.6.7 for association analyses via a two-step procedure as

567 detailed in⁵⁸. In brief, the first step fits a whole genome regression model for individual trait 568 predictions based on genetic data using the leave one chromosome out (LOCO) scheme. We 569 used a set of high-quality genotyped variants: minor allele frequency (MAF)>5%, minor allele count (MAC)>100, genotyping rate >99%, Hardy-Weinberg equilibrium (HWE) test $p>10^{-15}$, 570 <5% missingness and linkage-disequilibrium (LD) pruning (1000 variant windows, 100 sliding 571 windows and $r^2 < 0.8$). Traits where the step 1 regression failed to converge due to case 572 imbalances were subsequently excluded from subsequent analyses. The LOCO phenotypic 573 574 predictions were used as offsets in step 2 which performs variant association analyses using the approximate Firth regression detailed in⁵⁸ when the *p*-value from the standard logistic 575 576 regression score test is below 0.01. Standard errors (SEs) were computed from the effect size 577 estimate and the likelihood ratio test p-value. To avoid issues related to severe case imbalance 578 and extremely rare variants, we limited association test to phenotypes with >100 cases and for 579 variants with MAC≥5 in total samples and MAC≥3 in cases and controls. The number of 580 variants used for analyses varies for different diseases as a result of the MAC cut-off for 581 different disease prevalence. The association models in both steps also included the following covariates: age, age², sex, age^{*}sex, age²*sex, first 10 genetic principle components (PCs). 582

583

584 Association analyses in FG were performed using mixed model logistic regression method SAIGE v0.39⁵⁹. Age, sex, 10 PCs and genotyping batches were used as covariates. For null 585 586 model computation for each endpoint each genotyping batch was included as a covariate for an endpoint if there were at least 10 cases and 10 controls in that batch to avoid convergence 587 588 issues. One genotyping batch need be excluded from covariates to not have them saturated. We 589 excluded Thermo Fisher batch 16 as it was not enriched for any particular endpoints. For 590 calculating the genetic relationship matrix, only variants imputed with an INFO score >0.95 in 591 all batches were used. Variants with >3% missing genotypes were excluded as well as variants

592 with MAF<1%. The remaining variants were LD pruned with a 1Mb window and r^2 threshold 593 of 0.1. This resulted in a set of 59,037 well-imputed not rare variants for GRM calculation. 594 SAIGE options for null computation were: "LOCO=false, numMarkers=30, 595 traceCVcutoff=0.0025, ratioCVcutoff=0.001". Association tests were performed phenotypes 596 with case counts >100 and for variants with minimum allele count of 3 and imputation info >0.6597 were used.

598

We additionally performed sex-specific associations for a subset of gender-specific diseases (60 female diseases and in 50 disease clusters, 14 male diseases and in 13 disease clusters) in both FG and UKB using the same approach without inclusion of sex-related covariates (Supplementary Table 2)

603

We performed fixed-effect inverse-variance meta-analysis combining summary effect sizes and standard errors for overlapping variants with matched alleles across FG and UKB using METAL⁶⁰.

607

608 Definition and refinement of significant regions

To define significance, we used a combination of (1) multiple testing corrected threshold of $p<2x10^{-9}$, $0.05/(\sim 26.8x10^6)$ [sum (mean number of variants tested per disease cluster)], to account for the fact that some traits are highly correlated disease subtypes, (2) concordant direction of effect between UKB and FG associations, and (3) p<0.05 in both UKB and FG.

613

614 We defined independent trait associations through LD-based ($r^2=0.1$) clumping ±500Kb

around the lead variants using PLINK⁶¹, excluding the HLA region (chr6:25.5-34.0Mb) which

616 is treated as one region due to complex and extensive LD patterns. We then merged overlapping

617 independent regions (\pm 500Kb) and further restricted each independent variant ($r^{2}=0.1$) to the

618 most significant sentinel variant for each unique gene. For defining region associations across

- 619 traits, we merged overlapping independent regions for each individual trait.
- 620

621 Cross reference with known genetic associations

622 We cross-referenced the sentinel variants and their proxies $(r^2>0.2)$ for significant associations 623 $(p < 5x10^{-8})$ of mapped Experimental Factor Ontology (EFO) terms and their descendants in GWAS Catalog¹⁰ and PhenoScanner¹¹. To be more conservative with reporting of novel 624 625 associations, we also considered whether the most-severe associated gene in our analyses were reported in GWAS Catalog and PhenoScanner. In addition, we also queried our sentinel 626 variants in ClinVar¹² to define known associations with rarer genetic diseases and further 627 628 manually curated novel associations for previous genome-wide significant ($p < 5x10^{-8}$) 629 associations.

630

631 Biomarker associations of lead variants

For the lead sentinel variants, we performed association analyses using the two-step REGENIE
approach described above with 117 biomarkers including anthropometric traits, physical
measurements, clinical haematology measurements, blood and urine biomarkers available in
UKB (detailed in Supplementary Table 8).

636

637 Drug target mapping and enrichment

We mapped the annotated gene for each sentinel variant to drugs using the therapeutic target database (TTD)²⁶. We retained only drugs which have been approved or are in clinical trial stages. For enrichment analysis of approved drugs with genetic associations, we used Fisher's exact test on the proportion of significant genes targeted by approved drug against a

background of all approved drugs in TTD^{26} (n=595) and 20,437 protein coding genes from Ensembl annotations⁶².

644

645 Mendelian randomization (MR) analyses

646 F5 and F10 effect on pulmonary embolism (PE) risk

The missense variants rs4525 and rs61753266 in F5 and F10 genes were taken as genetic instruments for MR analyses. To assess potential that each factor level is causally associated with PE we employed two-sample MR using summary statistics, with effect of the variants on their respective factor levels obtained from previous large scale (protein quantitative trait loci) pQTL studies^{13,15}. Let β_{XY} denote the estimated causal effect of a factor level on PE risk and β_X , β_Y be the genetic association with a factor level (FV, FX or FXa) and PE risk respectively. Then, the MR ratio-estimate of β_{XY} is given by:

$$\beta_{XY} = \frac{\beta_Y}{\beta_X}$$

655 where the corresponding standard error $se(\beta_{XY})$, computed to leading order, is:

656
$$\operatorname{se}(\beta_{XY}) = \frac{\operatorname{se}(\beta_Y)}{|\beta_X|}$$

657

658 Clustered MR

To assess evidence of several distinct causal mechanisms by which atrial fibrillation (AF) may influence pulse rate (PR) we used MR-Clust⁴⁷. In brief, MR-Clust is a purpose-built clustering algorithm for use in univariate MR analyses. It extends the typical MR assumption that a risk factor can influence an outcome via a single causal mechanism⁶³ to a framework that allows one or more mechanisms to be detected. When a risk-factor affects an outcome via several mechanisms, the set of two-stage ratio-estimates can be divided into clusters, such that variants within each cluster have similar ratio-estimates. As shown in⁴⁷, two or more variants are

666 members of the same cluster if and only if they affect the outcome via the same distinct causal 667 pathway. Moreover, the estimated causal effect from a cluster is proportional to the total causal 668 effect of the mechanism on the outcome. We included variants within clusters where the 669 probability of inclusion >0.7. We used MR-Clust algorithm allowing for singletons/outlier 670 variants to be identified as their own "clusters" to reflect the large but biologically plausible 671 effect sizes seen with rare and low frequency variants.

672

673 Bioinformatic analyses of motif and expression for METTL11B

674 We searched [Ala/Pro/Ser]-Pro-Lys motif containing proteins using the "peptide search" function on UniProt⁶⁴, filtering for reviewed Swiss-Prot proteins and proteins listed in Human 675 Protein Atlas (HPA)³⁸ (n=7,656). We obtained genes with elevated expression in 676 cardiomyocytes (n=880) from HPA based on the criteria: "cell type category rna: 677 678 cardiomyocytes; cell type enriched, group enriched, cell type enhanced" as defined by HPA in 679 (https://www.proteinatlas.org/humanproteome/celltype/Muscle+cells#cardiomyocytes [accessed 20/03/2021]) with filtering for those with valid UniProt IDs (Swiss-Prot, n=863). 680 681 Enrichment test was performed using Fisher's exact test. Additionally, we performed 682 enrichment analyses using any Ala/Pro/Ser]-Pro-Lys motif positioned within the N-terminal 683 half of the protein (n=4,786).

685 Acknowledgements

686 We thank all the participants, contributors and researchers of UK Biobank and FinnGen (and its participating biobanks) for making data available for this study. We thank the UK Biobank 687 688 Exome Sequencing Consortium (AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, 689 Bristol-Myers Squibb, Pfizer, Regeneron and Takeda) for generation the whole exome 690 sequencing data and Regeneron Genetics Centre for initial quality control of the exome 691 sequencing data. The FinnGen project is funded by two grants from Business Finland (HUS 692 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., 693 AstraZeneca UK Ltd, Biogen MA Inc., Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual 694 695 Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech 696 Inc, and Novartis AG. We thank Susanna Lemmelä for her contribution to FinnGen data 697 curation. We further thank Yi-Qing Yang, Tim Footz, Michael Walter, Amelia Aránega, 698 Francisco Hernández-Torres, Elodie Morel and Gilles Millat for their contributions to the 699 functional characterisation of PITX2c. PITX2 functional work was supported in part by grants 700 from the National Natural Science Fund of China (81070153), the Personnel Development 701 Foundation of Shanghai, China (2010019), and the Key Program of Basic Research of 702 Shanghai, China (10JC1414002), and by the Canadian Institutes of Health Research (grants 703 MOP-111072 and MOP-130373 to Mohamed Chahine). Asma Mechakra was supported by a 704 bursary of the French Ministry of Research and Technology (MRT).

705

706 Author contributions

Conceptualization and experimental design: B.B.S., H.R.; methodology: B.B.S., H.R., C.N.F.,
C.C., M.J.D.; analysis: B.B.S., M.I.K., C.N.F., A.M., C.C., E.M., J.B.W., Biogen Biobank

- 709 Team; experimental work: A.M., G.C., M.C., P.C.; FinnGen protocols and analysis: M.I.K.,
- A.P., M.J.D., FinnGen; writing: B.B.S., H.R.; all authors critically reviewed the manuscript.
- 711

712 Correspondence

- 713 Correspondence and requests for materials should be addressed to B.B.S.
- 714 (<u>bbsun92@outlook.com</u>) or H.R. (<u>heiko.runz.@gmail.com</u>).
- 715

medRxiv preprint doi: https://doi.org/10.1101/2021.10.14.21265023; this version posted October 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figures and Tables 716

717 Figure 1. Coding genetic associations with disease. Manhattan plot for novel associations and 718 allelic enrichment surface plots are provided as Interactive Supplementary Figures 1 and 2. (a) 719 Summary of sentinel variant associations. Size of the point is proportional to effect size. $-\log_{10}(p)$ 720 capped at $-\log_{10}(10^{-50})$. Labels highlight pleiotropic associations (≥ 5 trait clusters). Colours indicate disease groups. Shape indicate novel/known (grey circles) associations. Dotted horizontal lines: -721 $\log_{10}(2\times10^{-9})$ [brown] and $-\log_{10}(5\times10^{-8})$ [grey]. (b). Comparison of sentinel variant MAF between 722 723 UKB and FG. (c) Effect size against MAF of sentinel variants. Dashed lines indicate MAF of 0.1% 724 (left) and 1% (right). (d) Surface plot of effects of cohort specific allele enrichment on inverse 725 variant weighted meta-analysis z-scores (IVW uplift) across MAFs (up to MAF 1%). Uplift is 726 defined as the ratio of meta-analysed IVW Z-score to the Z-score of an individual study (details in 727 Supplementary Information). (e) Density plot of MAF for sentinel variants for known vs novel 728 associations.





731

Figure 2. (a) Simplified diagram of the coagulation cascade. Factors (in roman numerals, "a" 733 734 represents activated) with genetic association with PE highlighted in orange. Blue line (round end) indicates inhibitory effect of APC on VIIIa and Va. (b) Schematic of potential pathway from 735 736 missense variants in F5 and F10 to PE risk. Factor V Leiden variant had null associations with F5 levels ($\beta_{F5 \text{ levels}}=0.21$, p=0.091). Dashed blue lines suggest effect of the variants on PE risk which we 737 738 assume under MR framework acts through factor levels (solid blue lines). Grey box and arrows

- 739 represent known pathway for Factor V Leiden mutation.
- 740 GOF: Gain of function, APC: Activated protein C, MR: Mendelian randomisation, PE: Pulmonary 741 embolism.
- 742



744

745 Figure 3. Biomarker associations with sentinel variants. (a) Heatmap of sentinel associations with

746 **biomarkers.** Only significant associations ($p < 10^{-6}$) displayed. Left side indicates chromosome with

747 cyan indicating MHC region. Right-side: sentinel association with disease by group (colours). Top

748 colours: category of biomarkers. (b) Forest plot of associations between SLC34A1 deletion (rs1460573878) with haematological and biochemistry biomarkers. P<0.05 displayed. (c) Forest

749 750 plot of associations between CHEK2 deletion (rs555607708) with haematological biomarkers.



752 Figure 4. Genetic and functional insights into AF.

753 (a) Clustered MR plot of AF loci on pulse rate. Only variants with cluster inclusion probability>0.7 754 are included. Left to right: CWAS loci (sentinels), Overlapping CWAS and AF GWAS loci, All AF 755 GWAS loci from Nielsen et al. (with zoomed inset), All AF GWAS loci with permuted pulse (null, 756 with zoomed inset). (b) Functional effect of PITX2c Pro41Ser variant (rs143452464) in vitro. Left: 757 schematic of the location of the Pro41Ser variant in PITX2c as compared to the PITX2a splicing 758 alternative. AD1: common sequence, HD: homeodomain, ID1: transcriptional inhibitory domain 1, 759 AD2: second common sequence, ID2: transcriptional inhibitory domain 2. Pro41Ser is within the N-760 terminal domain (grey), near to the 5-AA sequence (33 to 37 red, LAMAS) important for transcriptional 761 activity of the N-terminal of PITX2c. Middle: Reporter gene assays in TM-1 cells. Luciferase values 762 from activation of the SLC13A3-reporter plasmids (n=3) were normalized to β -galactosidase 763 (expressed from the transfection control plasmid), relative to the ratio for empty expression vector plus non-deleted SLC13A3 reporter ("-163/+165"). The reporter plasmid designated as "-163/+165 Δ " 764 765 contains a deletion of 8bp corresponding to the predicted PITX2 binding site. Right: qRT-PCR 766 analysis of HL-1 cells transfected with PITX2c recombinant plasmids. Effect of Pro41Ser PITX2c 767 variant expression on Cx40, Cx43, KCNQ1, KCNH2, SCN1B and SCN5A. *p<0.05, **p<0.01.







773 Table 1. Genes with sentinel variants enriched >4 fold in either UKB or FG. All

774 enrichment $p < 5 \times 10^{-5}$.

Gene	rsID (protein change)	CHR	A0/A1	A1 freq UKB/FG%	log2 FE (FG/UKB)	OMIM gene phenotype relationships	CWAS gene phenotype relationships
CHEK2	rs17879961 (l200T) rs555607708 ¹ (T410fs)	22	A/G AG/-	0.04/2.99% 0.24/0.64%	6.25 1.42	Cancer (breast, prostate, colorectal, osteosarcoma); Li- Fraumeni syndrome	rs17879961:G – benign meningeal neoplasm rs555607708:del (2.8x FG enriched) – Cancer (breast, thyroid, colorectal (benign)); uterine leiomyoma; ovarian cysts; PCOS
DBH	rs77273740 (R79W)	9	C/T	0.10/4.95%	5.69	Orthostatic hypotension	Hypertension (IA)
PITX2	rs143452464 (P41S)	4	G/A	0.02/1.01%	5.42	Anterior segment dysgenesis; Axenfeld-Rieger syndrome, ring dermoid of cornea	Arrythmia and AF
SLC24A5	rs1426654 (T111A)	15	A/G	0.09/1.13%	3.67	Skin/hair/eye pigmentation (dark); oculocutaneous albinism	Non-epithelial cancer of skin (other) (IA)
CFHR5	rs565457964 (E163fs)	1	C/CAA	0.32/3.96%	3.66	Nephropathy due to CFHR5 deficiency	Degeneration of macula and posterior pole of retina (IA)
ANKH	rs146886108 (R187Q)	5	C/T	0.72/0.07%	-3.28	Chondrocalcinosis; craniometaphyseal dysplasia	Type 2 diabetes mellitus (IA)
ALDH16A1	rs150414818 (P527R)	19	C/G	0.10/0.95%	3.23	-	Gout
LRRK1	rs41531245 (T967M)	15	C/T	0.09/0.76%	3.15	-	Contracture of palmar fascia; fasciitis; umbilical hernia
CFI	rs141853578 (G119R)	4	C/T	0.11/0.01%	-3.10	Atypical haemolytic uremic syndrome; age-related macular degeneration; CFI deficiency	Retinal disorders (other)
FLG	rs61816761 (R501*) rs138381300 ¹ (S761fs)	1	G/A CACTG/-	2.45/0.29% 2.45/1.35%	-3.10 -0.85	Atopic dermatitis; ichthyosis vulgaris	rs61816761:A – dermatitis (other) rs138381300:del (1.8x UKB enriched) – asthma; non-epithelial cancer of skin (other)
SOS2	rs72681869 (P191R)	14	G/C	1.09/0.15%	-2.84	Noonan syndrome	Hypertension (IA)
XPA	rs144725456 (H244R)	9	T/C	0.01/0.06%	2.61	Xeroderma pigmentosum	Non-epithelial cancer of skin (other)
CDC25A	rs146179438 (Q24H)	3	C/A	1.52/8.72%	2.52	-	Kidney and urinary stones (IA)
F10	rs61753266 (E142K)	13	G/A	0.33/1.83%	2.46	Factor X deficiency	PE and pulmonary heart disease (inverse association)
TNXB	rs61745355 (G2848R) rs10947230 ¹ (R2704H) rs1150752 ¹ (T302A)	6	C/T C/T T/C	2.22/11.86% 5.96/14.75% 13.29/9.17%	2.42 1.31 -0.54	Ehlers-Danlos syndrome; vesicoureteral reflux	rs61745355:T – lymphoma rs10947230:T – lichen planus rs1150752:C – chronic hepatitis; other inflammatory liver diseases; atherosclerosis
SLC39A8	rs13107325 (A391T)	4	C/T	7.40/1.46%	-2.35	Congenital disorder of glycosylation	Shoulder lesions
CLPTM1	rs150484293 (L140F)	19	C/T	0.35/0.07%	-2.33	-	Dementia
ELL2	rs141299831 (S18L)	5	G/A	0.02/0.12%	2.29	-	Benign neoplasm of other and ill- defined parts of digestive system
CASP7	rs141266925 (F214L)	10	T/C	0.31/1.5%	2.29	-	Cataracts
BRCA1	rs80357906 (Q1777fs)	17	T/TG	0.001/0.01%	2.21	Cancer (breast, ovarian, pancreatic); Fanconi anaemia	Breast cancer
SCN5A	rs45620037 (T220I)	3	G/A	0.11/0.49%	2.20	Sudden infant death syndrome; dilated cardiomyopathy; arrythmia ²	Arrythmia and AF
CACNA1D	rs1250342280 (F1943del)	3	CCTT/C	0.60/0.14%	-2.09	Primary aldosteronism, seizures, and neurologic abnormalities; sinoatrial node dysfunction and deafness	Hypertension
WNT10A	rs121908120 (F228I)	2	T/A	2.72/0.65%	-2.06	Odontoonychodermal dysplasia; Schopf-Schulz-Passarge syndrome; selective tooth agenesis	Follicular cysts of skin and subcutaneous tissue (IA)

775 776

 $^{1}\mbox{Other}$ sentinel variants in the gene with <4 FE

777 778 779 ²Sudden infant death syndrome; atrial fibrillation; Brugada syndrome; progressive and non-progressive heart block; long QT syndrome, sick sinus syndrome; ventricular fibrillation

FE: fold enrichment; IA: inverse association; PCOS: polycystic ovarian syndrome; PE: pulmonary embolism; AF: atrial 780 fibrillation

References 782

783 1 Claussnitzer, M. et al. A brief history of human disease genetics. Nature 577, 179-784 189, doi:10.1038/s41586-019-1879-7 (2020). 785 Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. 2 786 Nature 562, 203-209, doi:10.1038/s41586-018-0579-z (2018). 787 3 Van Hout, C. V. et al. Exome sequencing and characterization of 49,960 individuals 788 in the UK Biobank. Nature 586, 749-756, doi:10.1038/s41586-020-2853-0 (2020). 789 4 Szustakowski, J. D. et al. Advancing Human Genetics Research and Drug Discovery 790 through Exome Sequencing of the UK Biobank. medRxiv, 2020.2011.2002.20222232, 791 doi:10.1101/2020.11.02.20222232 (2020). 792 5 Wang, Q. et al. Surveying the contribution of rare variants to the genetic architecture 793 of human disease through exome sequencing of 177,882 UK Biobank participants. 794 bioRxiv, 2020.2012.2013.422582, doi:10.1101/2020.12.13.422582 (2020). 795 6 Peltonen, L., Jalanko, A. & Varilo, T. Molecular genetics of the Finnish disease 796 heritage. Hum Mol Genet 8, 1913-1923, doi:10.1093/hmg/8.10.1913 (1999). Lim, E. T. et al. Distribution and medical impact of loss-of-function variants in the 797 7 798 Finnish founder population. PLoS Genet 10, e1004494, 799 doi:10.1371/journal.pgen.1004494 (2014). 800 Locke, A. E. et al. Exome sequencing of Finnish isolates enhances rare-variant 8 801 association power. Nature 572, 323-328, doi:10.1038/s41586-019-1457-z (2019). 802 9 Hassan, S. et al. High-resolution population-specific recombination rates and their 803 effect on phasing and genotype imputation. Eur J Hum Genet, doi:10.1038/s41431-804 020-00768-8 (2020). 805 Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide 10 806 association studies, targeted arrays and summary statistics 2019. Nucleic acids 807 research 47, D1005-D1012, doi:10.1093/nar/gky1120 (2019). 808 11 Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype 809 associations. Bioinformatics (Oxford, England) 32, 3207-3209, doi:10.1093/bioinformatics/btw373 (2016). 810 811 12 Landrum, M. J. et al. ClinVar: improving access to variant interpretations and 812 supporting evidence. Nucleic acids research 46, D1062-D1067, 813 doi:10.1093/nar/gkx1153 (2018). 814 Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73-79, 13 815 doi:10.1038/s41586-018-0175-2 (2018). 816 Forberg, E., Huhmann, I., Jimenez-Boj, E. & Watzke, H. H. The impact of 14 817 Glu102Lys on the factor X function in a patient with a doubly homozygous factor X 818 deficiency (Gla14Lys and Glu102Lys). Thromb Haemost 83, 234-238 (2000). 819 15 Suhre, K. et al. Connecting genetic risk to disease end points through the human 820 blood plasma proteome. Nat Commun 8, 14357-14357, doi:10.1038/ncomms14357 821 (2017). 822 Kujovich, J. L. Factor V Leiden thrombophilia. Genetics in Medicine 13, 1-16, 16 823 doi:10.1097/GIM.0b013e3181faa0f2 (2011). 824 17 de Vries, P. S. et al. A meta-analysis of 120 246 individuals identifies 18 new loci for 825 fibrinogen concentration. Hum Mol Genet 25, 358-370, doi:10.1093/hmg/ddv454 826 (2016). 827 Wassel, C. L. et al. Association of genomic loci from a cardiovascular gene SNP 18 828 array with fibrinogen levels in European Americans and African-Americans from six

829		cohort studies: the Candidate Gene Association Resource (CARe). Blood 117, 268-
830	10	2/5, doi:10.1182/blood-2010-06-289546 (2011).
831	19	Simurda, T. <i>et al.</i> Genetic Variants in the FGB and FGG Genes Mapping in the Beta
832		and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative
833 834		Fibrinogen Disorders Associated with a Thrombotic Phenotype. Int J Mol Sci 21, doi:10.3390/ijms21134616 (2020).
835	20	Lapointe, J. Y. <i>et al.</i> NPT2a gene variation in calcium nephrolithiasis with renal
836	-	phosphate leak. <i>Kidney Int</i> 69 , 2261-2267, doi:10.1038/sj.ki.5000437 (2006).
837	21	Halbritter, J. et al. Fourteen monogenic genes account for 15% of
838		nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26, 543-551,
839		doi:10.1681/ASN.2014040388 (2015).
840	22	Schlingmann, K. P. et al. Autosomal-Recessive Mutations in SLC34A1 Encoding
841		Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia. JAm
842		Soc Nephrol 27, 604-614, doi:10.1681/ASN.2014101025 (2016).
843	23	Hinds, D. A. et al. Germ line variants predispose to both JAK2 V617F clonal
844		hematopoiesis and myeloproliferative neoplasms. <i>Blood</i> 128 , 1121-1128,
845		doi:10.1182/blood-2015-06-652941 (2016).
846	24	Sellick, G. S., Sullivan, K., Catovsky, D. & Houlston, R. S. CHEK2*1100delC and
847		risk of chronic lymphocytic leukemia. Leuk Lymphoma 47, 2659-2660,
848		doi:10.1080/10428190600942462 (2006).
849	25	Yan, K. et al. Normal platelet counts mask abnormal thrombopoiesis in patients with
850		chronic myeloid leukemia. Oncol Lett 10, 2390-2394, doi:10.3892/ol.2015.3502
851		(2015).
852	26	Wang, Y. et al. Therapeutic target database 2020: enriched resource for facilitating
853		research and early development of targeted therapeutics. <i>Nucleic Acids Res</i> 48,
854		D1031-D1041, doi:10.1093/nar/gkz981 (2020).
855	27	Nelson, M. R. et al. The support of human genetic evidence for approved drug
856		indications. Nat Genet 47, 856-860, doi:10.1038/ng.3314 (2015).
857	28	King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice
858		as likely to be approved? Revised estimates of the impact of genetic support for drug
859		mechanisms on the probability of drug approval. PLoS Genet 15, e1008489,
860		doi:10.1371/journal.pgen.1008489 (2019).
861	29	Võsa, U. et al. Unraveling the polygenic architecture of complex traits using blood
862		eQTL metaanalysis. <i>bioRxiv</i> , 447367, doi:10.1101/447367 (2018).
863	30	Girotra, M. et al. The Current Understanding of the Endocrine Effects From Immune
864		Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectr
865		2 , pky021, doi:10.1093/jncics/pky021 (2018).
866	31	Diogo, D. et al. Phenome-wide association studies across large population cohorts
867		support drug target validation. Nat Commun 9, 4285, doi:10.1038/s41467-018-06540-
868		3 (2018).
869	32	Nielsen, J. B. et al. Biobank-driven genomic discovery yields new insight into atrial
870		fibrillation biology. Nature Genetics 50, 1234-1239, doi:10.1038/s41588-018-0171-3
871		(2018).
872	33	Roselli, C. et al. Multi-ethnic genome-wide association study for atrial fibrillation.
873		Nature genetics 50, 1225-1233, doi:10.1038/s41588-018-0133-9 (2018).
874	34	Thorolfsdottir, R. B. et al. A Missense Variant in PLEC Increases Risk of Atrial
875		Fibrillation. J Am Coll Cardiol 70, 2157-2168, doi:10.1016/i.iacc.2017.09.005 (2017).
876	35	Petkowski, J. J. et al. NRMT2 is an N-terminal monomethylase that primes for its
877		homologue NRMT1. <i>Biochem J</i> 456 , 453-462, doi:10.1042/BJ20131163 (2013).

 Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. Nat Genet 45, 580-585, doi:10.1038/ng.2653 (2013). Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419, doi:10.1126/science.1260419 (2015). Feghaly, J., Zakka, P., London, B., MacRae, C. A. & Refaat, M. M. Genetics of Atrial Fribrillation. J Am Heart Assoc 7, e009884, doi:10.1161/JAHA.118.009884 (2018). Chambers, J. C. et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet 42, 149-152, doi:10.1038/ng.516 (2010). Li, W. et al. SCN5A Variants: Association With Cardiae Disorders. Front Physiol 9, 1372, doi:10.3389/fphys.2018.01372 (2018). Gui, J. et al. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. PLoS One 5, e10985, doi:10.10371/journal.pone.0010985 (2010). Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiae sodium channel gene (SCN5A). J Clin Invest 112, 1019-1028, doi:10.1172/JC118062 (2003). Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 293, 447-454, doi:10.1001/jam.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. Biochim Biophys Acta 1863, 1799-1805, doi:10.1093/europace/eur048 (2014). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. Europace 16, 384-395, doi:10.1093/europace/eur048 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. Bioinformatics, doi:10.1093/ioinformatics/bta778 (2020). Sidhu, S.& Marine, J. E. Evaluating and managing bradycardia. Trends Cardiovasc Med 30, 265-272, doi:10.1016/j.tem	878 879 880	36	Dong, C. <i>et al.</i> An asparagine/glycine switch governs product specificity of human N-terminal methyltransferase NTMT2. <i>Commun Biol</i> 1 , 183, doi:10.1038/s42003-018-0196-2 (2018)
 Store Standard Strategy and Standard Standar	881	37	Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. Nat Genet 45.
 Uhlen, M. <i>et al.</i> Protomics. Tissue-based map of the human proteome. <i>Science</i> 347, 1260419, doi:10.1126/science.1260419 (2015). Feghaly, J., Zakka, P., London, B., MacRae, C. A. & Refaat, M. M. Genetics of Atrial Fibrillation. <i>J Am Heart Assoc</i> 7, e009884, doi:10.1161/JAHA.118.009884 (2018). Chambers, J. C. <i>et al.</i> Genetic variation in SCN10A influences cardiac conduction. <i>Nat Genet</i> 42, 149-152, doi:10.1038/ng.516 (2010). Li, W. <i>et al.</i> SCNSA Variants: Association With Cardiac Disorders. <i>Front Physiol</i> 9, 1372, doi:10.3389/fphys.2018.01372 (2018). Gui, J. <i>et al.</i> Multiple loss-of-function mechanisms contribute to SCNSA-related familial sick sinus syndrome. <i>PLoS One</i> 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. <i>et al.</i> Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCNSA). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. <i>et al.</i> Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 23, 447-454, doi:10.1001/jama.293.4447 (2005). Zaklyzminskaya, E. & Dzemeshkewich, S. The role of mutations in the SCN5A gene in cardiomyopathies. Biochim Biophys Acta 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/buinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Sycda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates sy	882	51	580-585 doi:10.1038/ng.2653 (2013)
 1260419, doi:10.1126/science.1260419 (2015). Feghaly, J., Zakka, P., London, B., MacRae, C. A. & Refaat, M. M. Genetics of Atrial Fibrillation. J. Am Heart Assoc 7, c009884, doi:10.1161/JAHA.118.009884 (2018). Chambers, J. C. et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet 42, 149-152, doi:10.1038/ng.516 (2010). Li, W. et al. SCN5A Variants: Association With Cardiac Disorders. Front Physiol 9, 1372, doi:10.3389/fphys.2018.01372 (2018). Gui, J. et al. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. PLoS One 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAM 203, 447-454, doi:10.1001/jama.293.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. Biochim Biophys Acta 1863, 1799-1805, doi:10.1016/jbbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. Europace 16, 384-395, doi:10.1093/bioinformatics/bta778 (2020). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. Bioinformatics, doi:10.1093/bioinformatics/bta778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing braycardia. Trends Cardiovasc Med 30, 265-272, doi:10.1016/j.tem.2019.07.001 (2020). Sidhu, S. & Matine, J. E. Evaluating and managing braycardia. Trends Cardiovasc Med 30, 265-272, doi:10.101016/j.tem.2019.07.001 (2020). Sidhu, S. & Matine,	883	38	Uhlen, M. <i>et al.</i> Proteomics. Tissue-based map of the human proteome. <i>Science</i> 347 .
 Feghaly, J., Zakka, P., London, B., MacRae, C. A. & Refaat, M. M. Genetics of Atrial Fibrillation. J Am Heart Assoc 7, e009884, doi:10.1161/JAHA.118.009884 (2018). Chambers, J. C. et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet 42, 149-152, doi:10.1038/ng.516 (2010). Li, W. et al. SCN5A Variants: Association With Cardiac Disorders. Front Physiol 9, 1372, doi:10.3389/fphys.2018.01372 (2018). Gui, J. et al. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. PLoS One 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 112, 1019-1028, doi:10.1172/ICI18062 (2003). Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAM 203, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathics. Biochim Biophys Acta 1863, 1799-1805, doi:10.1016/j.bbamer.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. Europace 16, 384-395, doi:10.1093/bioinformatics/btaa778 (2020). Siduu, S. & Manne, J. E. Evaluating and managing bradycardia. Trends Cardiovasc Med 30, 265-272, doi:10.1016/j.bbarne.2019.07.019.07.019.02.2019/2022 (2020). Siduu, S. & Matine, J. E. Evaluating and managing bradycardia. Trends Cardiovasc Med 30, 265-272, doi:10.1016/j.bcm.2019.07.01 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. J Physiol 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates	884	50	1260419. doi:10.1126/science.1260419 (2015).
 Fibrillation. J Am Heart Assoc 7, e009884, doi:10.1161/JAHA.118.009884 (2018). Chambers, J. C. et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet 42, 149-152, doi:10.1038/ng.516 (2010). Li, W. et al. SCN5A Variants: Association With Cardiac Disorders. Front Physiol 9, 1372, doi:10.338/9fphys.2018.01372 (2018). Gui, J. et al. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. PLoS One 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. Biochim Biophys Acta 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. Europace 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. Bioinformatics, doi:10.1016/j.bbamcr.2019.07.001 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. Trends Cardiovasc Med 30, c55-272, doi:10.1016/j.bcs.2012.02922 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. Trends Cardiovasc Med 30, c55-272, doi:10.1016/j.bcs.2012.0292.2012.012927 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schi120/Prenia. medRivi, 2020.2009.2012.201922	885	39	Feghaly, J., Zakka, P., London, B., MacRae, C. A. & Refaat, M. M. Genetics of Atrial
 Chambers, J. C. <i>et al.</i> Genetic variation in SCN10A influences cardiac conduction. <i>Nat Genet</i> 42, 149-152, doi:10.1038/ng.516 (2010). Li, W. <i>et al.</i> SCN5A Variants: Association With Cardiac Disorders. <i>Front Physiol</i> 9, 1372, doi:10.3389/fphys.2018.01372 (2018). Gui, J. <i>et al.</i> Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. <i>PLoS One</i> 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. <i>et al.</i> Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. <i>et al.</i> Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1013/bioinformatics/bta778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc Med</i> 30, 265-272, doi:10.10101/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JIP273123 (2017). Sedku, S. & Marine, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.12.20192922, (2020). Eich	886	59	Fibrillation <i>J Am Heart Assoc</i> 7, e009884, doi:10.1161/JAHA.118.009884 (2018).
 Nat Genet 42, 149-152, doi:10.1038/ng.516 (2010). Li, W. et al. SCN5A Variants: Association With Cardiac Disorders. Front Physiol 9, 1372, doi:10.3389/fphys.2018.01372 (2018). Gui, J. et al. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. <i>PLoS One</i> 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamer.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1016/j.tem.2019.07.001 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc Med</i> 30, 265-272, doi:10.1016/j.tem.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. et al. Missing heritability and strategies for finding th	887	40	Chambers, J. C. <i>et al.</i> Genetic variation in SCN10A influences cardiac conduction.
 Li, W. et al. SCN5A Variants: Association With Cardiac Disorders. Front Physiol 9, 1372, doi:10.3389/fphys.2018.01372 (2018). Gui, J. et al. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. <i>PLoS One</i> 5, e10983, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathics. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/curopace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1016/j.tcm.2019.07.001 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv, 2020.2009 (2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/mf2809 (2010). Howl	888		Nat Genet 42 , 149-152, doi:10.1038/ng.516 (2010).
 1372, doi:10.3389/fphys.2018.01372 (2018). Gui, J. et al. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. <i>PLoS One</i> 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiae sodium channel gene (SCN5A). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCIIR062 (2003). Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.91.2.20192922 (2020). Eicher, F. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Ge	889	41	Li, W. <i>et al.</i> SCN5A Variants: Association With Cardiac Disorders. <i>Front Physiol</i> 9.
 Gui, J. et al. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. <i>PLoS One</i> 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamer.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1016/j.tcm.2019.07.001 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s1585-020-0332-x (2020).	890		1372. doi:10.3389/fphys.2018.01372 (2018).
 familial sick sinus syndrome. <i>PLoS One</i> 5, e10985, doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. <i>et al.</i> Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCNSA). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. <i>et al.</i> Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/cut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tem.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M.,	891	42	Gui, J. <i>et al.</i> Multiple loss-of-function mechanisms contribute to SCN5A-related
 doi:10.1371/journal.pone.0010985 (2010). Benson, D. W. <i>et al.</i> Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. <i>et al.</i> Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathics. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamer.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/202.09.12.20192922 (2020). Eichler, E. <i>E. et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of Kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Eichler, E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat </i>	892		familial sick sinus syndrome. <i>PLoS One</i> 5 , e10985.
 Benson, D. W. <i>et al.</i> Congenital sick sinus syndrome caused by recessive mutations in the cardiae sodium channel gene (SCN5A). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. <i>et al.</i> Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathics. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013).<	893		doi:10.1371/journal.pone.0010985 (2010).
 the cardiac sodium channel gene (SCN5A). <i>J Clin Invest</i> 112, 1019-1028, doi:10.1172/JCI18062 (2003). Olson, T. M. <i>et al.</i> Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/cut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of	894	43	Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in
 doi:10.1172/JCI18062 (2003). 44 Olson, T. M. <i>et al.</i> Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). 45 Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathics. <i>Biochim Biophys Acta</i> 1863, 1799-1805, 46 Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). 47 Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). 48 Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). 49 Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 51 Eichler, E. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrd20809 (2010). 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Bio</i>	895		the cardiac sodium channel gene (SCN5A). J Clin Invest 112, 1019-1028,
 44 Olson, T. M. <i>et al.</i> Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). 45 Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). 46 Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/curopace/cut348 (2014). 47 Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). 48 Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc Med</i> 30, 265-272, doi:10.1016/j.tem.2019.07.001 (2020). 49 Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.9.12.20192922 (2020). 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 52 Honge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nt2749 (2013). 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants	896		doi:10.1172/JCI18062 (2003).
 atrial fibrillation. <i>JAMA</i> 293, 447-454, doi:10.1001/jama.293.4.447 (2005). Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd251 (2013). Denny, J. C. et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat</i> <i>Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. et al. A catalog of associations between	897	44	Olson, T. M. et al. Sodium channel mutations and susceptibility to heart failure and
 45 Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). 46 Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). 47 Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). 48 Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). 49 Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>med</i>	898		atrial fibrillation. JAMA 293, 447-454, doi:10.1001/jama.293.4.447 (2005).
 in cardiomyopathies. <i>Biochim Biophys Acta</i> 1863, 1799-1805, doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.2021804, doi:10.1101/020210.28.20221804 (2021) 	899	45	Zaklyazminskaya, E. & Dzemeshkevich, S. The role of mutations in the SCN5A gene
 doi:10.1016/j.bbamcr.2016.02.014 (2016). Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.2021804, doi:10.1101/0202.10.28 20221804 (2021). 	900		in cardiomyopathies. Biochim Biophys Acta 1863, 1799-1805,
 46 Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node: effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). 47 Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). 48 Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). 49 Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021). 	901		doi:10.1016/j.bbamcr.2016.02.014 (2016).
 effects of HCN4 mutations on the hyperpolarization-activated current. <i>Europace</i> 16, 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/ht2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2012.2021804 (2021). 	902	46	Verkerk, A. O. & Wilders, R. Pacemaker activity of the human sinoatrial node:
 384-395, doi:10.1093/europace/eut348 (2014). Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). 838 Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). 49 Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nb2.7749 (2013). 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2012.022.80221804, doi:10.1101/2020 10.28.20221804 (2021). 	903		effects of HCN4 mutations on the hyperpolarization-activated current. Europace 16,
 47 Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). 48 Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). 49 Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat</i> <i>Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	904		384-395, doi:10.1093/europace/eut348 (2014).
 genetic variants in Mendelian randomization with similar causal estimates. <i>Bioinformatics</i>, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.20218.20221804, doi:10.101/2020 10.28 20221804 (2021) 	905	47	Foley, C. N., Mason, A. M., Kirk, P. D. W. & Burgess, S. MR-Clust: Clustering of
 Bioinformatics, doi:10.1093/bioinformatics/btaa778 (2020). Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.101/2020 10.28 20221804 (2021) 	906		genetic variants in Mendelian randomization with similar causal estimates.
 908 48 Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i> 909 <i>Med</i> 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). 910 49 Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial 911 fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 912 (2017). 913 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes 914 and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 915 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 916 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying 917 causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 918 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 919 407-421, doi:10.1038/s41585-020-0332-x (2020). 920 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through 921 human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 922 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of 923 electronic medical record data and genome-wide association study data. <i>Nat</i> 924 <i>Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). 925 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and 926 COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, 927 doi:10.1101/2020 10.28 20221804 (2021) 	907		Bioinformatics, doi:10.1093/bioinformatics/btaa778 (2020).
 Med 30, 265-272, doi:10.1016/j.tcm.2019.07.001 (2020). Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. J Physiol 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. Nat Rev Urol 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. et al. A catalog of associations between rare coding variants and COVID-19 outcomes. medRxiv, 2020.2010.2028.20221804, doi:10.1101/2020 10.28.2021804 (2021) 	908	48	Sidhu, S. & Marine, J. E. Evaluating and managing bradycardia. <i>Trends Cardiovasc</i>
 910 49 Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). 913 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 916 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 918 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). 920 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 922 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). 925 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	909		Med 30 , 265-272, doi:10.1016/j.tcm.2019.07.001 (2020).
 fibrillation and rhythm control. <i>J Physiol</i> 595, 4019-4026, doi:10.1113/JP273123 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	910	49	Syeda, F., Kirchhof, P. & Fabritz, L. PITX2-dependent gene regulation in atrial
 (2017). Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021). 	911		fibrillation and rhythm control. J Physiol 595, 4019-4026, doi:10.1113/JP273123
 913 50 Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes 914 and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 915 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 916 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying 917 causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 918 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 919 407-421, doi:10.1038/s41585-020-0332-x (2020). 920 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through 921 human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 922 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of 923 electronic medical record data and genome-wide association study data. <i>Nat 924 Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). 925 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and 926 COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, 927 doi:10.1101/2020.10.28.20221804 (2021) 	912		(2017).
 and implicates synaptic biology in schizophrenia. <i>medRxiv</i>, 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28 20221804 (2021). 	913	50	Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes
 2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020). 51 Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). 52 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). 53 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). 54 Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). 55 Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	914		and implicates synaptic biology in schizophrenia. <i>medRxiv</i> ,
 Fichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	915		2020.2009.2012.20192922, doi:10.1101/2020.09.12.20192922 (2020).
 causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010). Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	916	51	Eichler, E. E. <i>et al.</i> Missing heritability and strategies for finding the underlying
 Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17, 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	917		causes of complex disease. <i>Nat Rev Genet</i> 11, 446-450, doi:10.1038/nrg2809 (2010).
 407-421, doi:10.1038/s41585-020-0332-x (2020). Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat</i> <i>Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	918	52	Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. <i>Nat Rev Urol</i> 17,
 Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. <i>Nat Rev Drug Discov</i> 12, 581-594, doi:10.1038/nrd4051 (2013). Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. <i>Nat</i> <i>Biotechnol</i> 31, 1102-1110, doi:10.1038/nbt.2749 (2013). Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and COVID-19 outcomes. <i>medRxiv</i>, 2020.2010.2028.20221804, doi:10.1101/2020.10.28.20221804 (2021) 	919		40/-421, doi:10.1038/s41585-020-0332-x (2020).
921human genetics. Nat Rev Drug Discov 12, 581-594, doi:10.1038/nrd4051 (2013).92254Denny, J. C. et al. Systematic comparison of phenome-wide association study of923electronic medical record data and genome-wide association study data. Nat924Biotechnol 31, 1102-1110, doi:10.1038/nbt.2749 (2013).9255555Kosmicki, J. A. et al. A catalog of associations between rare coding variants and926COVID-19 outcomes. medRxiv, 2020.2010.2028.20221804,927doi:10.1101/2020.10.28.20221804 (2021)	920	53	Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through
92254Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of923electronic medical record data and genome-wide association study data. Nat924Biotechnol 31 , 1102-1110, doi:10.1038/nbt.2749 (2013).9255555Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and926COVID-19 outcomes. <i>medRxiv</i> , 2020.2010.2028.20221804,927doi:10.1101/2020.10.28.20221804 (2021)	921	E 4	numan genetics. Nat Rev Drug Discov 12, $581-594$, doi:10.1038/nrd4051 (2013).
925electronic medical record data and genome-wide association study data. Nat924Biotechnol 31 , 1102-1110, doi:10.1038/nbt.2749 (2013).92555926COVID-19 outcomes. medRxiv, 2020.2010.2028.20221804,927doi:10.1101/2020.10.28.20221804 (2021)	922	54	Denny, J. C. <i>et al.</i> Systematic comparison of phenome-wide association study of
924Diolectinol 51, 1102-1110, doi:10.1038/hbt.2/49 (2013).92555Kosmicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and926 $COVID-19$ outcomes. <i>medRxiv</i> , 2020.2010.2028.20221804,927doi:10.1101/2020.10.28.20221804 (2021)	923 024		Piotochurol 21, 1102, 1110, doi:10,1028/mbt 2740 (2012)
925 55 Rosinicki, J. A. <i>et al.</i> A catalog of associations between rare coding variants and 926 COVID-19 outcomes. <i>medRxiv</i> , 2020.2010.2028.20221804, 927 doi:10.1101/2020.10.28.20221804 (2021)	724 025	55	<i>Biolechnol</i> 31 , 1102-1110, 001.10.1030/1101.2/49 (2013).
927 doi:10.1101/2020.10.28.20221804 (2021)	923 976	55	COVID-19 outcomes medBriv 2020 2010 2028 20221804
	927		d_{0i} 10 1101/2020 10 28 20221804 (2021)

- 928 56 Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation 929 in 141,456 humans. Nature 581, 434-443, doi:10.1038/s41586-020-2308-7 (2020).
- 930 McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122, 57 931 doi:10.1186/s13059-016-0974-4 (2016).
- 932 Mbatchou, J. et al. Computationally efficient whole genome regression for 58 933 quantitative and binary traits. bioRxiv, 2020.2006.2019.162354, 934 doi:10.1101/2020.06.19.162354 (2020).
- 935 59 Zhou, W. et al. Efficiently controlling for case-control imbalance and sample 936 relatedness in large-scale genetic association studies. Nat Genet 50, 1335-1341, 937 doi:10.1038/s41588-018-0184-y (2018).
- 938 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of 60 939 genomewide association scans. Bioinformatics 26, 2190-2191, 940 doi:10.1093/bioinformatics/btq340 (2010).
- 941 Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and 61 942 richer datasets. Gigascience 4, 7, doi:10.1186/s13742-015-0047-8 (2015).
- 943 62 Yates, A. D. et al. Ensembl 2020. Nucleic Acids Res 48, D682-D688, 944 doi:10.1093/nar/gkz966 (2020).
- Burgess, S., Foley, C. N. & Zuber, V. Inferring Causal Relationships Between Risk 945 63
- 946 Factors and Outcomes from Genome-Wide Association Study Data. Annu Rev 947 Genomics Hum Genet 19, 303-327, doi:10.1146/annurev-genom-083117-021731 948 (2018).
- 949 UniProt, C. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res 64 950 49, D480-D489, doi:10.1093/nar/gkaa1100 (2021).
- 951